Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Neurocrine Biosciences Inc Market Cap
Based on ratings from 13 stock analysts, the Neurocrine Biosciences Inc stock price is expected to increase by 40.65% in 12 months. This is calculated by using the average 12-month stock price forecast for Neurocrine Biosciences Inc. The lowest target is $131 and the highest is $219. Please note analyst price targets are not guaranteed and could be missed completely.
NBIX is a stock in Health Care which has been forecasted to be worth $171.88 as an average. On the higher end, the forecast price is $219 USD by Jay Olson from Oppenheimer and on the lower end NBIX is forecasted to be $131 by from .
These are the latest 20 analyst ratings of NBIX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Akash Tewari Jefferies | Buy | $189 | Maintains | Aug 19, 2024 |
| Anupam Rama JP Morgan | Overweight | $181 | Maintains | Aug 7, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $190 | Maintains | Aug 5, 2024 |
| Brian Skorney Baird | Outperform | $180 | Maintains | Aug 2, 2024 |
| Yatin Suneja Guggenheim | Buy | $180 | Maintains | Aug 2, 2024 |
| David Hoang Citigroup | Neutral | $158 | Maintains | Aug 2, 2024 |
| Carter Gould Barclays | Overweight | $180 | Maintains | Aug 2, 2024 |
| Brian Abrahams RBC Capital | Sector Perform | $143 | Maintains | Aug 2, 2024 |
| Jay Olson Oppenheimer | Outperform | $219 | Maintains | Aug 2, 2024 |
| Ami Fadia Needham | Hold | Reiterates | Aug 1, 2024 | |
| Charles Duncan Cantor Fitzgerald | Overweight | $155 | Reiterates | Jul 25, 2024 |
| Ami Fadia Needham | Hold | Reiterates | Jul 25, 2024 | |
| Jeffrey Hung Morgan Stanley | Overweight | $170 | Maintains | Jul 12, 2024 |
| Anupam Rama JP Morgan | Overweight | $173 | Maintains | Jul 10, 2024 |
| Jeffrey Hung Morgan Stanley | Overweight | $160 | Maintains | Jun 12, 2024 |
| Laura Chico Wedbush | Outperform | $152 | Reiterates | May 29, 2024 |
| Ashwani Verma UBS | Buy | $193 | Maintains | May 28, 2024 |
| Cory Kasimov Evercore ISI Group | Outperform | $175 | Initiates | May 14, 2024 |
| David Hoang Citigroup | Neutral | $150 | Maintains | May 3, 2024 |
| Carter Gould Barclays | Overweight | $169 | Maintains | May 2, 2024 |
When did it IPO
1996
Staff Count
1,448
Country
United States
Sector/Industry
Healthcare/Drug Manufacturers - Specialty & Generic
CEO
Dr. Kevin C. Gorman Ph.D.
Market Cap
$15.40B
In 2023, NBIX generated $1.89B in revenue, which was a increase of 26.76% from the previous year. This can be seen as a signal that NBIX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 12 Sep 2024
Sentiment - NEGATIVE
Source - Reuters
Summary - Neurocrine Biosciences announced that its experimental drug failed to meet the primary endpoint in a mid-stage trial for enhancing cognitive function in schizophrenia patients.
Why It Matters - The failure of Neurocrine's drug trial raises concerns about its pipeline and future revenue potential, likely impacting stock performance and investor confidence.
Thu, 12 Sep 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Neurocrine Biosciences' Phase 2 study of luvadaxistat for schizophrenia cognitive impairment failed to meet its primary endpoint. The company will focus on Phase 3 development of NBI-1117568 and NBI-1065845.
Why It Matters - Failure of Luvadaxistat in Phase 2 trials raises concerns about Neurocrine Biosciences' drug pipeline, potentially impacting stock performance and investor confidence. Focus shifts to other candidates.
Tue, 10 Sep 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 2024 Cantor Global Healthcare Conference in New York on September 10, 2024, at 3:05 p.m.
Why It Matters - Neurocrine's participation in a major healthcare conference may signal upcoming developments or partnerships, potentially influencing stock performance and investor sentiment.
Sun, 01 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Nxera Pharma (TSE 4565) will receive a $35 million payment from Neurocrine Biosciences following the successful Phase 2 trial of NBI-1117568 for schizophrenia, to be recorded in Q3 2024.
Why It Matters - Nxera Pharma's $35 million payment from Neurocrine boosts its revenue, signaling successful trial outcomes, which may enhance investor confidence and affect stock performance positively.
Fri, 30 Aug 2024
Sentiment - NEUTRAL
Source - The Motley Fool
Summary - The biotech announced positive results from a phase 2 clinical trial for its schizophrenia drug, with one of the four doses showing clear efficacy.
Why It Matters - Positive phase 2 trial results for a schizophrenia drug indicate potential market approval, boosting the biotech's stock value and attractiveness to investors.
Thu, 29 Aug 2024
Sentiment - POSITIVE
Source - Benzinga
Summary - Neurocrine Biosciences (NASDAQ: NBIX) announced topline data from its Phase 2 clinical study of NBI-1117568 for treating schizophrenia in adults.
Why It Matters - Neurocrine's Phase 2 results for NBI-‘568 in schizophrenia can impact stock performance, pipeline valuation, and future market potential, influencing investor sentiment and decisions.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
